everyone. to day every morning, healthy Amneal family, many. possible Chirag, you who Thank and thank so to help make hard global the Good you, work for
on strategy are points chain laser and of strong how pharmaceutical engine growth focused medicine. diversified right will highly the an proof capable sustainable of be key strategy. touch executing track. we on supply areas to the excellence, company, that our global profiler of successes in XXXX clear I productive operational and on innovative We R&D are are The driving
operational First, the we service one driving industry. the in on remain focused best of and has Amneal efficiency as levels excellence
efficiencies As savings. production on about transferring operational for programs also our products for we to part excellence efforts XX of for many cost and long-term working drive globally, continuous cost improvement are
in expanding have particularly In by strengthened our addition, we our infrastructure, injectables. supply chain
injectables X while market the We our supply to facilities capacity XX have shortages. and face with production doubled lines, continue injectables
the are commercial successful drug long-term growth. At XXXs. same positioned no has time, our U.S. our conducted to to maintaining XXX high-quality of only XX Overall, global record. well FDA very ANDA sustainable the Amnneal support remain and list. about Since shortages we at pipeline to track help our stellar minor U.S. is committed injectable the products Importantly, U.S. operations scale quality with observations shortage or the XXXX, in address are inspections FDA nearly on
more is any generics, XX case complex idea less launches. growing This value the of track In the portfolio. is increased products, per cadence are these and of normal the of of than well year-to-date. it's our XXXX new company, pharmaceuticals the Amneal. innovation competitors above year. diversified It in Also, with XX Second, the number new our on that's XX for lifeblood and just is for of we certainly over launches
deep is pipeline launches we approval products new for year, next with after in pending and Our Accordingly, expect that. over XX years or development. XXX
complex we while shifted we efficiency improved operations. have also addition, of have innovations, towards the In our R&D
We are doing spend, better results in more a projects. which ROI R&D with less on
Behind on of pipeline have with Let solid me are R&D. we products, we are details XX spending of that, non-oral non-oral which which more share some XX have ANDAs FDA, products. Overall, XX% XX% solids.
be first XXX(b)(X) calcium to complex pipeline XX% categories XX Also, high-value our we we In have and which products new methylprednisolone Injectables, products. approval number injectables We we to first file gluconate is to approximately as with of products pipeline. in with have QX XX% a year-to-date, acetate, recently expected in and QX, ANDAs first shortage. In our filed Further, market, in or for to shifted bags advancing complex potassium of over high-value pending X bags. received of focus launched including ready-to-use to-XXX(b)X) we phosphate our are planned. our
injectables as We expect long-acting the well. to file several near term in
complex as a the in Pemry-DRTU. injectables cadence injectables, impactful see approved in AMN's new inhalation key of next we including area launch of As expect generics. After growth strong already XXXX, to we continue result, a
product the generic a tripped. under launch This of for coming important and upon overdose over-the-counter access NARCAN ANDA critical approval. improves look version pending a months, review, is priority Our to in we to
the we to for meter-dose X of biosimilars, added have first Pro. In are excellent pipeline. version have X generic inhaler QR we addition, key In molecules additional products X ANDAs and seeing our and oncology pending uptake
list We of are also integrated evaluating time. our opportunities and to for recent launches. upcoming see Please slide be vertically the over catalyst
specialty with to as to to on highlighted, FDA to last type month advance continue align R&D, the On we pipeline. path meeting Turning Chirag a XXX(b)(X) had to A successful we approval. work our IPXXXX,
As study of in agreed FDA, with QT routine patients. small the in a are healthy we completing process
study the NDA coming resubmit in the early We will in will our months, we and XXXX. complete
are working towards pending approval. We the half IPXXXX an XXXX launch FDA of second in diligently
advances critical which executing IPXXXX hand operational We over In strategy, drive care our as are standard summary, a for sustainable we Parkinson's and will to of innovation Tassos. excellence ability see together to our I now that driving innovation meaningfully growth. the to fueling are continue it patients.
